Breast and Cervical Cancer Bill Signed

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 12
Volume 9
Issue 12

WASHINGTON-President Clinton has signed the Breast and Cervical Cancer Prevention and Treatment Act of 2000 into law. The Act provides $990 million over 10 years to expand the treatment options for uninsured, low-income women diagnosed with breast or cervical cancer in a nationwide program run by the Centers for Disease Control and Prevention (CDC).

WASHINGTON—President Clinton has signed the Breast and Cervical Cancer Prevention and Treatment Act of 2000 into law. The Act provides $990 million over 10 years to expand the treatment options for uninsured, low-income women diagnosed with breast or cervical cancer in a nationwide program run by the Centers for Disease Control and Prevention (CDC).

The new law ends a situation that many physicians and patient advocates found incomprehensible. Prior to the new law, there was no federal program to treat women diagnosed through CDC’s 10-year-old National Breast and Cervical Cancer Early Detection Program. The Act creates a new optional Medicaid eligibility category to cover such treatment. The measure sets a federal matching formula with a ceiling of 85% and a floor of 65%. The formula varies from state to state.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Related Content